- Home
- GGB vs GH Comparison
GGB vs GH Comparison
Compare GGB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGB
- GH
- Stock Information
- Founded
- GGB 1901
- GH 2011
- Country
- GGB Brazil
- GH United States
- Employees
- GGB N/A
- GH N/A
- Industry
- GGB Steel/Iron Ore
- GH Medical Specialities
- Sector
- GGB Industrials
- GH Health Care
- Exchange
- GGB Nasdaq
- GH Nasdaq
- Market Cap
- GGB 5.7B
- GH 4.9B
- IPO Year
- GGB 1999
- GH 2018
- Fundamental
- Price
- GGB $3.50
- GH $68.90
- Analyst Decision
- GGB Strong Buy
- GH Strong Buy
- Analyst Count
- GGB 1
- GH 22
- Target Price
- GGB $3.80
- GH $66.27
- AVG Volume (30 Days)
- GGB 24.1M
- GH 2.0M
- Earning Date
- GGB 10-30-2025
- GH 10-29-2025
- Dividend Yield
- GGB 2.89%
- GH N/A
- EPS Growth
- GGB N/A
- GH N/A
- EPS
- GGB 0.29
- GH N/A
- Revenue
- GGB $12,681,996,398.00
- GH $828,849,000.00
- Revenue This Year
- GGB $6.34
- GH $28.28
- Revenue Next Year
- GGB $4.87
- GH $23.00
- P/E Ratio
- GGB $10.93
- GH N/A
- Revenue Growth
- GGB 6.96
- GH 28.74
- 52 Week Low
- GGB $2.27
- GH $20.82
- 52 Week High
- GGB $3.62
- GH $73.31
- Technical
- Relative Strength Index (RSI)
- GGB 67.94
- GH 58.54
- Support Level
- GGB $3.32
- GH $68.33
- Resistance Level
- GGB $3.44
- GH $73.31
- Average True Range (ATR)
- GGB 0.08
- GH 2.89
- MACD
- GGB 0.01
- GH 0.20
- Stochastic Oscillator
- GGB 97.37
- GH 64.18
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutors, mechanical construction bars, and reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives the majority of its revenue from the Brazil Operations segment.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.